PriceTargets.com logo

Nkarta - NKTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 532.91%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 2 Strong Buy Ratings
$2.37 As of 12/20/2024 06:45 PM ET
▲ +0.17 (7.73%)

This chart shows the closing price for NKTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nkarta Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NKTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NKTX

Analyst Price Target is $15.00
▲ +532.91% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Nkarta in the last 3 months. The average price target is $15.00, with a high forecast of $18.00 and a low forecast of $11.00. The average price target represents a 532.91% upside from the last price of $2.37.

This chart shows the closing price for NKTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Nkarta. This rating has held steady since September 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/21/2024MizuhoLower TargetOutperform ➝ Outperform$20.00 ➝ $16.00
11/11/2024HC WainwrightLower TargetBuy ➝ Buy$22.00 ➝ $18.00
11/8/2024Needham & Company LLCLower TargetBuy ➝ Buy$13.00 ➝ $11.00
10/9/2024RODMAN&RENSHAWUpgradeStrong-Buy
10/9/2024Rodman & RenshawInitiated CoverageBuy$14.00
8/15/2024HC WainwrightLower TargetBuy ➝ Buy$23.00 ➝ $22.00
8/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
8/14/2024Raymond JamesUpgradeOutperform ➝ Strong-Buy$16.00 ➝ $16.00
7/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
6/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
6/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
5/13/2024Needham & Company LLCLower TargetBuy ➝ Buy$15.00 ➝ $13.00
5/13/2024HC WainwrightBoost TargetBuy ➝ Buy$22.00 ➝ $23.00
5/10/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$16.00 ➝ $15.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00
3/26/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$15.00 ➝ $16.00
3/22/2024MizuhoLower TargetBuy ➝ Buy$31.00 ➝ $25.00
3/22/2024Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$13.00 ➝ $16.00
3/22/2024HC WainwrightLower TargetBuy ➝ Buy$22.00 ➝ $20.00
3/22/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00
3/5/2024MizuhoBoost TargetBuy ➝ Buy$9.00 ➝ $31.00
1/16/2024HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $22.00
12/12/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00
11/16/2023MizuhoLower TargetBuy ➝ Buy$15.00 ➝ $9.00
10/18/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00
10/18/2023HC WainwrightLower TargetBuy ➝ Buy$16.00 ➝ $10.00
10/17/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$13.00
8/14/2023MizuhoLower TargetBuy ➝ Buy$26.00 ➝ $15.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$16.00
8/11/2023Stifel NicolausLower Target$18.00 ➝ $15.00
8/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$19.00 ➝ $15.00
5/12/2023Stifel NicolausLower Target$21.00 ➝ $18.00
3/17/2023Needham & Company LLCReiterated RatingBuy$26.00
3/17/2023HC WainwrightReiterated RatingBuy$34.00 ➝ $30.00
12/22/2022OppenheimerDowngradeOutperform ➝ Market Perform
12/5/2022OppenheimerLower Target$36.00 ➝ $26.00
11/16/2022MizuhoLower TargetBuy$81.00 ➝ $26.00
11/10/2022OppenheimerLower TargetOutperform$50.00 ➝ $36.00
10/10/2022Canaccord Genuity GroupInitiated CoverageBuy$25.00
9/21/2022Cantor FitzgeraldReiterated RatingOverweight
8/12/2022Cantor FitzgeraldLower TargetOverweight$60.00 ➝ $38.00
7/28/2022Needham & Company LLCInitiated CoverageBuy$26.00
7/18/2022Leerink PartnersInitiated CoverageOutperform$30.00
4/26/2022Raymond JamesBoost TargetOutperform$17.00 ➝ $32.00
4/25/2022HC WainwrightBoost TargetBuy$25.00 ➝ $36.00
3/29/2022Cantor FitzgeraldReiterated RatingOverweight
3/11/2022Raymond JamesInitiated CoverageOutperform$17.00
3/8/2022HC WainwrightInitiated CoverageBuy$25.00
1/6/2022William BlairInitiated CoverageOutperform$35.00
11/18/2021Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$50.00
10/10/2021Evercore ISIReiterated RatingBuy$70.00
7/15/2021OppenheimerInitiated CoverageOutperform$75.00
6/29/2021Cantor FitzgeraldBoost TargetOverweight$71.00 ➝ $78.00
6/16/2021MizuhoReiterated RatingBuy$81.00
5/9/2021Evercore ISIReiterated RatingBuy$70.00
3/17/2021Cantor FitzgeraldReiterated RatingOverweight
12/23/2020MizuhoBoost TargetBuy$47.00 ➝ $81.00
12/7/2020MizuhoBoost TargetBuy$34.00 ➝ $47.00
8/4/2020Evercore ISIInitiated CoverageOutperform$55.00
8/4/2020Stifel NicolausInitiated CoverageBuy$41.00
8/4/2020MizuhoInitiated CoverageBuy$34.00
8/4/2020CowenInitiated CoverageOutperform
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 8 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 4 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Nkarta logo
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More

Today's Range

Now: $2.37
Low: $2.15
High: $2.40

50 Day Range

MA: $3.01
Low: $2.17
High: $4.34

52 Week Range

Now: $2.37
Low: $2.08
High: $16.24

Volume

1,912,837 shs

Average Volume

1,242,622 shs

Market Capitalization

$167.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of Nkarta?

The following Wall Street research analysts have issued research reports on Nkarta in the last year: Canaccord Genuity Group Inc., HC Wainwright, Mizuho, Needham & Company LLC, Raymond James, Rodman & Renshaw, and RODMAN&RENSHAW.
View the latest analyst ratings for NKTX.

What is the current price target for Nkarta?

0 Wall Street analysts have set twelve-month price targets for Nkarta in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 532.9%. HC Wainwright has the highest price target set, predicting NKTX will reach $18.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $11.00 for Nkarta in the next year.
View the latest price targets for NKTX.

What is the current consensus analyst rating for Nkarta?

Nkarta currently has 5 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NKTX will outperform the market and that investors should add to their positions of Nkarta.
View the latest ratings for NKTX.

What other companies compete with Nkarta?

Other companies that are similar to Nkarta include Stoke Therapeutics, Altimmune, CARGO Therapeutics, Exscientia and ORIC Pharmaceuticals. Learn More about companies similar to Nkarta.

How do I contact Nkarta's investor relations team?

Nkarta's physical mailing address is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 925-407-1049 and its investor relations email address is [email protected]. The official website for Nkarta is www.nkartatx.com. Learn More about contacing Nkarta investor relations.